Physician profile
Karen E Webb
NPI 1902819501
$4,103.47
in general payments reported to CMS, 2019-2025
30 companies · $1,260 in 2025
The $1,260 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $238 · 2022: $444 · 2023: $922 · 2024: $1,239 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,421.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $862.05 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $787.95 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $411.37 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $296.13 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $252.13 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $229.55 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $211.13 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $154.11 | 2023-2025 | Repatha, Otezla, Otezla |
| Lundbeck LLC | $119.80 | 2023-2025 | Rexulti |
| Dexcom, INC. | $106.12 | 2023-2024 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $79.07 | 2024-2025 | Ibsrela |
| Sumitomo Pharma America, INC. | $75.42 | 2023 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $66.86 | 2022 | |
| Aimmune Therapeutics, INC. | $51.71 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $43.93 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $41.57 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.96 | 2024-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $33.76 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.63 | 2021 | |
| Astellas Pharma US INC | $24.63 | 2024 | Veozah |
| Neurocrine Biosciences, INC. | $24.20 | 2023 | Ingrezza |
| Neurelis, INC. | $21.80 | 2025 | Valtoco |
| Axsome Therapeutics, INC. | $21.05 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.59 | 2021 | |
| Sk Life Science, INC. | $19.45 | 2023 | |
| Exact Sciences Corporation | $19.34 | 2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $18.78 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.10 | 2023 | Xarelto |
| Idorsia Pharmaceuticals US INC | $14.77 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $14.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.